The goal of this study is to analyse differences in monocyt activity, by analysis of cytokine levels in serum of healthy and OA patients.
ID
Source
Brief title
Condition
- Tendon, ligament and cartilage disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Differences in cytokine profiles between OA and healthy individuals of the
following cytokines: (IL-1β, IL-4, IL-6, IL-10, IL-13, TNF-α, IFNγ, OSM, OPG,
IL-1RA, TGF-β, IGF-1).
Secondary outcome
Not applicable
Background summary
Osteoarthritis (OA) is an invaliditating disorder, which can result in pain, a
decrease in mobility and inactivity. The underlying cause is degeneration of
the joint, leading to a decrease in the load-bearing capacity of the cartilage
(Cunningham, Am J Public Health 1984).
Although OA is usually considered as a local, age-related disorder, recent
observations demonstrate that systemical processes may play a part in disease
progression, which can lead to a change in composition of the blood
(unpublished data, Orthopaedics department of the UMCU). These recent
observations demonstrate that the cytokine level in blood of healthy patients
is different than that of OA patients. An altered monocyt activity may lie at
the foundations of this process.
One of the treatment strategies in OA is to interfere with intra-articualr
cytokine levels (Auw Yang, OA&C 2008). However, intereference with systemically
circulating proteins would possibly be even more effective. In order to develop
systemical therapies for treatment of OA, it is necessary to gain knowledhe on
cytokine profiles in serum of patients with OA. The discovery of altered
cytokine profiles, and thus of an altered monocyt activity, would possibly lead
to the development of therapies that interfere with OA in a systemical fashion.
Study objective
The goal of this study is to analyse differences in monocyt activity, by
analysis of cytokine levels in serum of healthy and OA patients.
Study design
In 20 healthy and 20 OA patients, 40 ml of blood will be acquired through
venapunction, followed by analysis of cytokineprofiles (IL-1β, IL-4, IL-6,
IL-10, IL-13, TNF-α, IFNγ, OSM, OPG, IL-1RA, TGF-β, IGF-1) by ELISA and by
Multiplex ELISA.
Study burden and risks
Burden: venapunction (once) which will take approximately 10 minutes
Risk: dizziness or fainting, haemorrhage on the place of injection
Heidelberglaan 100
3584 CX
Nederland
Heidelberglaan 100
3584 CX
Nederland
Listed location countries
Age
Inclusion criteria
- age higher than 18 years
- signed informed consent
- healthy: no diseases of musculoskeletal system
- OA: patients with OA, as diagnosed by an orthopaedic surgeon
Exclusion criteria
- prior joint replacement
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL25097.041.08 |